<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="11225" end="11233" sStart="10841" offset="384" sid="r8.suggest.v.0899" wn="3" wnkey="suggest%2:32:02::" annotator="brubin" text="A unique feature of GCTs is their origin from germ cells at a stage in development where they undergo epigenetic reprogramming [ 6 13 ] . The absence of this epigenetic modification in SGCTs is consistent with their GC-like nature as previously noted [ 6 14 ] . On the other hand, the extensive promoter hypermethylation seen in NSGCTs suggests a mechanistic role in their potential for embryonal and extra-embryonal lineage differentiation [ 6 14 ] . Establishment of DNA methylation in the mammalian genome is controlled by at least three DNA methyltransferases (DNMTs), DNMT1 , DNMT3a and DNMT3b [ 15 ] . The role of these DNMTs in differential de novo methylation in SGCT vs." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="15196" end="15201" sStart="null" offset="85" sid="r1.rule.v.0066" wn="2147483647" wnkey="null" annotator="sophiavv" text="Thus, role of partial methylation in down-regulating MGMT cannot be ruled out." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="15196" end="15201" sStart="null" offset="85" sid="r1.rule.v.0066" wn="2147483647" wnkey="null" annotator="anfahmy" text="Thus, role of partial methylation in down-regulating MGMT cannot be ruled out." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="15196" end="15201" sStart="null" offset="85" sid="r1.rule.v.0066" wn="2147483647" wnkey="null" annotator="adelpriore" text="Thus, role of partial methylation in down-regulating MGMT cannot be ruled out." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="6466" end="6472" sStart="null" offset="167" sid="null" wn="1" wnkey="normal%3:00:01::" annotator="veweser" text="Levels of expression of each gene were assessed by comparing with the respective control values, obtained from the averages calculated from 2 to 4 normal testes, after normalization against ACTB . All tumors with promoter hypermethylation of the MGMT and MLH1 genes exhibited an absence or down-regulated expression of the respective gene, while 8 of 10 cases with RASSF1A methylation and 3 of 5 tumors with RARB methylation showed down-regulated expression (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="21612" end="21618" sStart="null" offset="123" sid="r9.normal.j.0833" wn="1" wnkey="normal%3:00:01::" annotator="veweser" text="Nine cell lines derived from GCT have been previously described [ 8 ] . DNA and RNA isolated from four normal testes were used as controls." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="6466" end="6472" sStart="null" offset="167" sid="r9.normal.j.0741" wn="1" wnkey="normal%3:00:01::" annotator="veweser" text="Levels of expression of each gene were assessed by comparing with the respective control values, obtained from the averages calculated from 2 to 4 normal testes, after normalization against ACTB . All tumors with promoter hypermethylation of the MGMT and MLH1 genes exhibited an absence or down-regulated expression of the respective gene, while 8 of 10 cases with RASSF1A methylation and 3 of 5 tumors with RARB methylation showed down-regulated expression (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="6466" end="6472" sStart="null" offset="167" sid="null" wn="2147483645" wnkey="null" annotator="sophiavv" text="Levels of expression of each gene were assessed by comparing with the respective control values, obtained from the averages calculated from 2 to 4 normal testes, after normalization against ACTB . All tumors with promoter hypermethylation of the MGMT and MLH1 genes exhibited an absence or down-regulated expression of the respective gene, while 8 of 10 cases with RASSF1A methylation and 3 of 5 tumors with RARB methylation showed down-regulated expression (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="6466" end="6472" sStart="null" offset="167" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Levels of expression of each gene were assessed by comparing with the respective control values, obtained from the averages calculated from 2 to 4 normal testes, after normalization against ACTB . All tumors with promoter hypermethylation of the MGMT and MLH1 genes exhibited an absence or down-regulated expression of the respective gene, while 8 of 10 cases with RASSF1A methylation and 3 of 5 tumors with RARB methylation showed down-regulated expression (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="2150" end="2156" sStart="null" offset="26" sid="r9.normal.j.0307" wn="3" wnkey="normal%3:00:03::" annotator="cgozo" text="During the life span of a normal GC, extensive methylation reprogramming occurs [ 6 ] . However, the role of epigenetic changes in GCT etiology and biology are not well studied." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="6466" end="6472" sStart="null" offset="167" sid="null" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="Levels of expression of each gene were assessed by comparing with the respective control values, obtained from the averages calculated from 2 to 4 normal testes, after normalization against ACTB . All tumors with promoter hypermethylation of the MGMT and MLH1 genes exhibited an absence or down-regulated expression of the respective gene, while 8 of 10 cases with RASSF1A methylation and 3 of 5 tumors with RARB methylation showed down-regulated expression (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="27186" end="27192" sStart="null" offset="243" sid="r9.normal.j.0352" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="A tumor was considered to have lost expression when the gene showed complete lack of expression or at least 50% reduction from the normalized values obtained from the average calculated utilizing 2 to 4 normal testes." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="6466" end="6472" sStart="null" offset="167" sid="null" wn="2147483645" wnkey="null" annotator="anfahmy" text="Levels of expression of each gene were assessed by comparing with the respective control values, obtained from the averages calculated from 2 to 4 normal testes, after normalization against ACTB . All tumors with promoter hypermethylation of the MGMT and MLH1 genes exhibited an absence or down-regulated expression of the respective gene, while 8 of 10 cases with RASSF1A methylation and 3 of 5 tumors with RARB methylation showed down-regulated expression (Table 1)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="21966" end="21972" sStart="null" offset="248" sid="r9.normal.j.0474" wn="2" wnkey="normal%3:00:02::" annotator="anfahmy" text="Genomic DNA was treated with sodium bisulphite as previously described [ 33 ] . Placental DNA treated in vitro with Sss I methyltransferase (New England Biolabs, Beverly, MA) and similarly treated normal lymphocyte DNA were used as controls for methylated and unmethylated templates, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="8512" end="8518" sStart="null" offset="123" sid="r9.level.n.0705" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="One cell line (T-218A) showed no promoter hypermethylation of MGMT by MSP and no detectable levels of mRNA expression by RT-PCR but expression was reactivated after 5-Aza-2' deoxycytidine treatment." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="3091" end="3098" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="veweser" text="We assessed 92 GCT DNAs representing all histologic subsets of NSGCT, and SGCT, and four normal testes for methylation status of CpG &lt;b&gt;islands&lt;/b&gt; of 21 gene promoters by methylation-specific PCR (MSP) (Fig." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="15037" end="15044" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="veweser" text="The MSP method detects only methylation of full-length CpG &lt;b&gt;islands&lt;/b&gt; and cannot identify partial methylation of the promoters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="18387" end="18394" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="veweser" text="Transcriptional silencing of genes resulting from DNA hypermethylation of CpG &lt;b&gt;islands&lt;/b&gt; is reversed by treatment of the hypo-methylating agent 5-aza-2'-deoxycytidine in a dose and duration-dependent manner." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="793" end="799" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="veweser" text="A nonrandom pattern of promoter hypermethylation has been noted in specific genes in specific tumor types, although some genes are commonly methylated in diverse tumors [ 3 4 ] . The extent of aberrant promoter hypermethylation and its association with loss of gene function in cancer suggests that CpG &lt;b&gt;island&lt;/b&gt; methylation is an important mechanism in inactivating tumor suppressor genes (TSGs)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="190" end="197" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="veweser" text="Promoter methylation has been well recognized as an important epigenetic change in the development of cancer [ 1 ] . Normally, CpG &lt;b&gt;islands&lt;/b&gt; in the promoter regions of a number of genes are present in an unmethylated state [ 2 ] . Aberrant methylation of CpG &lt;b&gt;islands&lt;/b&gt; in promoters is characteristic of several genes in cancer leading to loss of gene expression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="332" end="339" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="veweser" text="Promoter methylation has been well recognized as an important epigenetic change in the development of cancer [ 1 ] . Normally, CpG &lt;b&gt;islands&lt;/b&gt; in the promoter regions of a number of genes are present in an unmethylated state [ 2 ] . Aberrant methylation of CpG &lt;b&gt;islands&lt;/b&gt; in promoters is characteristic of several genes in cancer leading to loss of gene expression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="15037" end="15044" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="tofox" text="The MSP method detects only methylation of full-length CpG &lt;b&gt;islands&lt;/b&gt; and cannot identify partial methylation of the promoters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="18387" end="18394" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="tofox" text="Transcriptional silencing of genes resulting from DNA hypermethylation of CpG &lt;b&gt;islands&lt;/b&gt; is reversed by treatment of the hypo-methylating agent 5-aza-2'-deoxycytidine in a dose and duration-dependent manner." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="793" end="799" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="tofox" text="A nonrandom pattern of promoter hypermethylation has been noted in specific genes in specific tumor types, although some genes are commonly methylated in diverse tumors [ 3 4 ] . The extent of aberrant promoter hypermethylation and its association with loss of gene function in cancer suggests that CpG &lt;b&gt;island&lt;/b&gt; methylation is an important mechanism in inactivating tumor suppressor genes (TSGs)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="190" end="197" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="tofox" text="Promoter methylation has been well recognized as an important epigenetic change in the development of cancer [ 1 ] . Normally, CpG &lt;b&gt;islands&lt;/b&gt; in the promoter regions of a number of genes are present in an unmethylated state [ 2 ] . Aberrant methylation of CpG &lt;b&gt;islands&lt;/b&gt; in promoters is characteristic of several genes in cancer leading to loss of gene expression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="332" end="339" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="tofox" text="Promoter methylation has been well recognized as an important epigenetic change in the development of cancer [ 1 ] . Normally, CpG &lt;b&gt;islands&lt;/b&gt; in the promoter regions of a number of genes are present in an unmethylated state [ 2 ] . Aberrant methylation of CpG &lt;b&gt;islands&lt;/b&gt; in promoters is characteristic of several genes in cancer leading to loss of gene expression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="3091" end="3098" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="jeneale" text="We assessed 92 GCT DNAs representing all histologic subsets of NSGCT, and SGCT, and four normal testes for methylation status of CpG &lt;b&gt;islands&lt;/b&gt; of 21 gene promoters by methylation-specific PCR (MSP) (Fig." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="3091" end="3098" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" annotator="carichter" text="We assessed 92 GCT DNAs representing all histologic subsets of NSGCT, and SGCT, and four normal testes for methylation status of CpG &lt;b&gt;islands&lt;/b&gt; of 21 gene promoters by methylation-specific PCR (MSP) (Fig." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-1-8.anc" start="26887" end="26892" sStart="null" offset="0" sid="null" wn="3" wnkey="image%1:06:00::" annotator="veweser" text="The PCR products were run on 1.5% agarose gels, visualized by ethidium bromide staining and quantitated using the Kodak Digital &lt;b&gt;Image&lt;/b&gt; Analysis System (Kodak, New Haven, CT)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="16518" end="16522" sStart="null" offset="670" sid="r10.high.j.0423" wn="1" wnkey="high%3:00:02::" annotator="cgozo" text="Epigenetic gene silencing of the MGMT confers enhanced sensitivity to alkylating agents in cancer [ 24 25 ] . Lack of methylation, on the other hand, associates with high-risk of death [ 25 26 ] . It has been suggested that the high-levels of MGMT proteins contribute to a drug-resistant phenotype [ 27 ] . More than 90% of newly diagnosed GCTs and 70-80% of patients who present metastatic disease are cured with cisplatin-based chemotherapy [ 28 ] . However, 20-30% of the patients with metastatic disease exhibit resistance to the cisplatin curative regimen leading to high mortality in this group." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="22001" end="22009" sStart="null" offset="283" sid="r10.control.n.0837" wn="4" wnkey="control%1:09:02::" annotator="veweser" text="Genomic DNA was treated with sodium bisulphite as previously described [ 33 ] . Placental DNA treated in vitro with Sss I methyltransferase (New England Biolabs, Beverly, MA) and similarly treated normal lymphocyte DNA were used as controls for methylated and unmethylated templates, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="21639" end="21647" sStart="null" offset="150" sid="r10.control.n.0412" wn="4" wnkey="control%1:09:02::" annotator="brubin" text="Nine cell lines derived from GCT have been previously described [ 8 ] . DNA and RNA isolated from four normal testes were used as controls." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="10253" end="10259" sStart="null" offset="38" sid="r10.common.j.0693" wn="4" wnkey="common%5:00:00:familiar:02" annotator="veweser" text="Here we show that hypermethylation is common in NSGCT and rare in SGCT." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="946" end="952" sStart="null" offset="37" sid="r10.common.j.0631" wn="4" wnkey="common%5:00:00:familiar:02" annotator="cgozo" text="Germ cell tumors (GCTs) are the most common cancer in men between the ages 20-40 with an incidence of 4.2 cases per 100,000 [ 5 ] . GCTs arise by transformation of spermatogonial lineage cells and display pluripotentiality for embryonal and extra-embryonal lineage differentiation [ 6 ] . Histologically, they may present as undifferentiated germ cell (GC)-like seminomas (SGCTs) or highly differentiated nonseminomas (NSGCTs)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="2885" end="2891" sStart="null" offset="29" sid="r10.common.j.0902" wn="4" wnkey="common%5:00:00:familiar:02" annotator="anfahmy" text="Promoter hypermethylation is common in NSGCT and rare in SGCT" />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="21241" end="21246" sStart="null" offset="210" sid="r10.board.n.0120" wn="1" wnkey="board%1:14:00::" annotator="brubin" text="The tumor biopsies were ascertained from patients evaluated at Memorial Sloan-Kettering Cancer Center (MSKCC) as described previously [ 11 ] after appropriate institutional review board approval." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="11007" end="11014" sStart="null" offset="166" sid="r11.absence.n.0242" wn="1" wnkey="absence%1:26:00::" annotator="anfahmy" text="A unique feature of GCTs is their origin from germ cells at a stage in development where they undergo epigenetic reprogramming [ 6 13 ] . The absence of this epigenetic modification in SGCTs is consistent with their GC-like nature as previously noted [ 6 14 ] . On the other hand, the extensive promoter hypermethylation seen in NSGCTs suggests a mechanistic role in their potential for embryonal and extra-embryonal lineage differentiation [ 6 14 ] . Establishment of DNA methylation in the mammalian genome is controlled by at least three DNA methyltransferases (DNMTs), DNMT1 , DNMT3a and DNMT3b [ 15 ] . The role of these DNMTs in differential de novo methylation in SGCT vs." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="2480" end="2487" sStart="null" offset="12" sid="r11.absence.n.0064" wn="1" wnkey="absence%1:26:00::" annotator="anfahmy" text="We found an absence of promoter hypermethylation in SGCT and acquisition of unique patterns of promoter hypermethylation in NSGCT." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-1-8.anc" start="2480" end="2487" sStart="null" offset="12" sid="r11.absence.n.0064" wn="1" wnkey="absence%1:26:00::" annotator="adelpriore" text="We found an absence of promoter hypermethylation in SGCT and acquisition of unique patterns of promoter hypermethylation in NSGCT." />
  </sentences>
</list>